Addressing Sterile Manufacturing Challenges
Keynote SeriesPharmaceutical Technology and BioPharm International are sponsoring a Keynote Series discussion on addressing sterile manufacturing challenges on the INTERPHEX 2016 Exhibit Hall Innovation Stage. Admission is free to any attendee with an exhibit hall pass.
Wednesday April 27, 3:30–4:30 pm
Panel Discussion: Addressing Sterile Manufacturing Challenges
Sterile injectables have been in extremely short supply, and industry efforts have been focusing on root causes involving infrastructure, quality, and efficiency. Experts involved in this work discuss recent initiatives, and offer insights into what must be done to prevent injectables shortages in the future.
Speakers:
Maik Jornitz, President, G-CON Manufacturing Inc
Bill Hartzel, Director – Strategic Execution, Catalent Pharma Solutions
Chris Procyshyn, CEO, Vanrx Pharmasystems
Anil-Kumar Busimi, Director, Strategic Marketing and Innovation, Schott
Vinod Vilivalam, Director of Strategic Marketing and Technical Development, Americas, Daikyo Seiko
To register: http://www.interphex.com/pharmtech
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
